Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MediWound (MDWD) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for MediWound (MDWD) over the last 13 years, with Sep 2025 value amounting to $32.7 million.

  • MediWound's Cash & Equivalents rose 405.59% to $32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year increase of 405.59%. This contributed to the annual value of $9.2 million for FY2024, which is 22.85% down from last year.
  • As of Q2 2021, MediWound's Revenue - Interest and Investment Income stood at $26.2 million, which was down 15.66% from $31.1 million recorded in Q4 2020.
  • In the past 5 years, MediWound's Revenue - Interest and Investment Income registered a high of $49.9 million during Q2 2019, and its lowest value of $26.2 million during Q2 2021.
  • Over the past 3 years, MediWound's median Cash & Equivalents value was $6.5 million (recorded in 2024), while the average stood at $5.2 million.
  • Its Revenue - Interest and Investment Income has fluctuated over the past 5 years, first skyrocketed by 35.74% in 2019, then crashed by 30.59% in 2020.
  • Over the past 5 years, MediWound's Revenue - Interest and Investment Income (Quarterly) stood at $44.1 million in 2017, then dropped by 20.07% to $35.3 million in 2018, then rose by 15.06% to $40.6 million in 2019, then decreased by 23.45% to $31.1 million in 2020, then fell by 24.30% to $26.2 million in 2021.
  • Its Cash & Equivalents was $32.7 million in Q3 2025, compared to -$8.1 million in Q2 2025 and -$7.8 million in Q1 2025.